Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THALIDOMIDE vs REVLIMID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and b FGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.
Newly diagnosed multiple myeloma (in combination with dexamethasone),Leprosy (erythema nodosum leprosum)
Multiple myeloma (in combination with dexamethasone),Myelodysplastic syndromes (MDS) associated with deletion 5q abnormality,Mantle cell lymphoma,Follicular lymphoma (in combination with rituximab)
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Terminal elimination half-life of approximately 3-5 hours in patients with normal renal function. Half-life is prolonged in renal impairment (up to 9 hours in severe impairment).
Primarily non-enzymatic hydrolysis in plasma; minor CYP2C19-mediated hydroxylation.
Lenalidomide is primarily metabolized via hydrolysis, with minor involvement of CYP1A2 and CYP3A4. The major route of elimination is renal excretion of unchanged drug; approximately 67% of the dose is excreted unchanged in urine.
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Primarily renal excretion as unchanged drug (approximately 67% of the dose in urine over 24 hours) with minor fecal elimination (<4%).
Approximately 55-65% bound to albumin and alpha-1-acid glycoprotein.
Approximately 30% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 1.2 L/kg (range 0.8-1.5 L/kg), indicating extensive distribution into body tissues.
Volume of distribution (Vd) is approximately 0.6-1.0 L/kg, indicating distribution into total body water and some tissue binding.
Oral bioavailability is approximately 90-100% (absolute bioavailability).
Absolute oral bioavailability is approximately 33% (range 20-50%) due to first-pass metabolism. Food does not significantly alter bioavailability.
No dosage adjustment required for renal impairment. Thalidomide is minimally renally excreted; however, use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
For Cr Cl ≥60 m L/min: start at 10 mg daily; Cr Cl 30-60 m L/min: start at 5 mg daily; Cr Cl <30 m L/min: 5 mg every other day; for dialysis patients: 5 mg three times weekly after dialysis.
Child-Pugh Class A: 100 mg daily. Child-Pugh Class B: Reduce to 50 mg daily or 100 mg every other day. Child-Pugh Class C: Not recommended due to lack of safety data.
No specific Child-Pugh based dose adjustments provided in labeling; use caution and monitor for toxicity in hepatic impairment.
Not approved for use in children; safety and efficacy not established. In investigational settings, 2-5 mg/kg/day orally divided every 12 hours, with a maximum of 100 mg/day.
Safety and efficacy not established; not recommended for pediatric use outside clinical trials.
No specific dose adjustment, but start at low end of dosing range (50-100 mg daily) due to increased risk of sedation, constipation, and peripheral neuropathy. Monitor renal function, though no dose adjustment required.
No specific dose adjustment based solely on age; monitor renal function and adjust per renal guidelines as elderly often have decreased Cr Cl.
THALIDOMIDE IS CONTRAINDICATED IN PREGNANCY (CATEGORY X). Severe birth defects (phocomelia, other fetal anomalies) and fetal death. Must not be used by women who are pregnant or may become pregnant. Also contraindicated in sexually active women of childbearing potential unless using two reliable forms of contraception. Male patients must use latex condom during sexual contact with pregnant or childbearing-potential women. [See REMS program]
Revlimid (lenalidomide) can cause fetal harm. Women of childbearing potential must use effective contraception and undergo pregnancy testing prior to and during therapy. There is an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. The drug is contraindicated in pregnant women.
Thromboembolism (DVT/PE) - increased risk with concurrent dexamethasone. Severe peripheral neuropathy (monitor for paresthesias). Neutropenia, thrombocytopenia. Dizziness, somnolence. Hypersensitivity reactions (angioedema, Stevens-Johnson syndrome). Bradycardia, syncope. Increased LFTs. Seizures. Amyloid deposition. Angioedema. Increases risk of hepatotoxicity. Use in renal/hepatic impairment with caution.
Hematologic toxicity: Neutropenia and thrombocytopenia are common, requiring dose adjustments.,Thromboembolism: Increased risk of DVT, PE, and stroke; consider prophylactic anticoagulation or antiplatelet therapy.,Second primary malignancies: Risk of development of other cancers (e.g., AML, MDS) in patients receiving lenalidomide.,Hepatotoxicity: Elevations of liver enzymes have been reported.,Allergic reactions: Including angioedema and Stevens-Johnson syndrome.,Renal impairment: Requires dose adjustment; monitor renal function.
Pregnancy (Category X) - fetal toxicity. Women of childbearing potential not using two forms of contraception. Men not using latex condom. Hypersensitivity to thalidomide. Use with drugs that cause peripheral neuropathy. Severe neutropenia (ANC < 750/μL).
Pregnancy (due to teratogenicity),Women of childbearing potential not using effective contraception,Hypersensitivity to lenalidomide or any component of the formulation
Avoid grapefruit juice (may increase exposure). No specific food restrictions otherwise.
Avoid grapefruit and grapefruit juice; they may increase lenalidomide exposure. No other significant food interactions are known.
Thalidomide is contraindicated in pregnancy. First trimester exposure causes severe limb defects (phocomelia, amelia), ear anomalies, ocular defects, and cardiac malformations in up to 50% of exposed fetuses. Second and third trimester exposure risks fetal growth restriction and neurodevelopmental effects. No safe trimester exists.
REVLIMID (lenalidomide) is an analog of thalidomide, a known human teratogen. It is absolutely contraindicated in pregnancy. Fetal exposure can cause severe, life-threatening birth defects including limb reduction, cardiac anomalies, and neural tube defects. Risk is highest during the first trimester but extends throughout gestation.
Thalidomide is excreted in human milk; M/P ratio is approximately 0.5. Breastfeeding is contraindicated due to potential adverse effects in the infant, including sedation and neutropenia.
It is unknown if lenalidomide is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated. M/P ratio is not available.
No dose adjustment studies in pregnancy exist because thalidomide is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased clearance, altered distribution) are expected but dose adjustments should not be attempted; alternative therapy must be used.
There are no dose adjustments for pregnancy because the drug is contraindicated; it must be discontinued immediately if pregnancy occurs. No pharmacokinetic studies in pregnancy are available.
Strict REMS program required due to teratogenicity; screen for pregnancy before and during therapy. Monitor for thromboembolism, neuropathy, and bradycardia. Dose reduction needed in renal impairment. Can cause tumor lysis syndrome in multiple myeloma.
Monitor for thromboembolic events; use with aspirin or anticoagulant prophylaxis. Perform pregnancy tests weekly during first month, then monthly in women of childbearing potential. Dose reduce for Cr Cl <60 m L/min. Avoid in severe hepatic impairment (Child-Pugh C).
Never use during pregnancy – can cause severe birth defects.,Women must use two reliable contraceptives and undergo monthly pregnancy tests.,Men must use condoms during sexual activity with a pregnant woman or a woman who could become pregnant.,Avoid blood donation while on therapy and for 4 weeks after stopping.,Report numbness, tingling, drowsiness, or rash immediately.
Do not share this medication with others; it can cause severe birth defects.,Use two forms of contraception or abstain from sex during treatment and for 4 weeks after stopping.,Report any new shortness of breath, chest pain, or leg swelling immediately.,Avoid grapefruit and grapefruit juice while taking this medication.,Do not donate blood during treatment and for 4 weeks after stopping.
"Thalidomide, a sedative-hypnotic with central nervous system (CNS) depressant properties, can additively enhance the CNS-depressant effects of tiagabine, an anticonvulsant that potentiates GABAergic neurotransmission. This combination increases the risk of excessive sedation, dizziness, psychomotor impairment, and respiratory depression. Patients may experience compounded neurological effects, leading to reduced alertness and increased fall risk, particularly during initiation or dose escalation."
"Thalidomide, a known central nervous system depressant, can potentiate the sedative effects of fluticasone propionate, particularly when administered at high doses or via inhalation. This additive CNS depression may lead to increased sedation, dizziness, and impairment of cognitive or motor function, posing risks for falls or accidents. Patients should be warned against driving or operating heavy machinery until the combined effects are known."
"Thalidomide, an immunomodulatory agent, may antagonize the laxative effect of picosulfuric acid by reducing gastrointestinal motility through its anticholinergic-like properties and potential to cause constipation. This interaction could lead to decreased effectiveness of picosulfuric acid in promoting bowel evacuation, potentially resulting in inadequate bowel preparation for procedures or incomplete relief of constipation. Clinically, patients may experience reduced stool output or delayed onset of action, requiring alternative or additional laxative therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THALIDOMIDE vs REVLIMID, answered by our medical review team.
THALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.. REVLIMID is a Immunomodulatory Agent that works by Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and b FGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THALIDOMIDE and REVLIMID depend on the specific clinical indication. These are both Immunomodulatory Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THALIDOMIDE is: 100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.. The standard adult dose of REVLIMID is: 5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THALIDOMIDE and REVLIMID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THALIDOMIDE is classified as Category D/X. Thalidomide is contraindicated in pregnancy. First trimester exposure causes severe limb defects (phocomelia, amelia), ear anomalies, ocular defects, and cardiac malformations in u. REVLIMID is classified as Category C. REVLIMID (lenalidomide) is an analog of thalidomide, a known human teratogen. It is absolutely contraindicated in pregnancy. Fetal exposure can cause severe, life-threatening birth. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.